Management of chronic venous disease: The example of Daflon 500 mg

Phlebolymphology

Volumn 16, Issue 4, 2009, Pages 321-330

  Ramelet, Albert Adrien ^a  

^a NONE   (Switzerland)

Author keywords

Chronic venous disease; Drugs; Flavonoids; Management

Indexed keywords

ANTHOCYANIN; BENZARONE; COUMARIN; DAFLON; DIOSMIN; DOBESILATE CALCIUM; ESCIN; GINKGO BILOBA EXTRACT; MONOXERUTIN; NAFTAZONE; PROANTHOCYANIDIN; RUSCUS EXTRACT; RUTOSIDE; TROXERUTIN;

CAPILLARY PERMEABILITY; CELL INTERACTION; CLINICAL TRIAL; COMPRESSION THERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; LEG EDEMA; LEG ULCER; LEUKOCYTE; PATHOPHYSIOLOGY; SCLEROTHERAPY; ULCER HEALING; VEIN DISEASE; VEIN PAIN; VEIN TONE;

EID: 77949348052     PISSN: 12860107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Robertson L, Evans C, Fowkes FGR. Epidemiology of chronic venous disease. Phlebology 2008;23:103-111.
2. Rabe E, Pannier-Fischer F, Bromen K, et al. Bonner Venenstudie der Deutschen Gesellschaft für Phlebologie. Phlebologie 2003;32:1-14.
3. Chiesa R, Marone EM, Limoni C, Volonte M, Schaefer E, Petrini O. Chronic venous insufficiency in Italy: the 24-cities cohort study. Eur J Vasc Endovasc Surg 2005;30:422-429.
4. Evans CJ, Fowkes FGR, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population. Edinburgh Vein Study. J Epidemiol Community Health 1999;53:149-153.
5. McLafferty RB, Passman MA, Caprini JA, et al. Increasing awareness about venous disease: the American Venous Forum expands the National Screening Program. J Vasc Surg 2008;48:394-399.
6. Porter JM, Moneta GL. International Consensus Committee on Chronic Venous Disease: reporting standards on venous disease: an update. J Vasc Surg 1995;21:635-645.
7. Eklöf B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004;40:1248-1252.
8. Eklöf B, Perrin M, Delis KT, Rutherford RB; the VEIN-Term Transatlantic Interdisciplinary Faculty. Updated terminology of chronic venous disorders: the VEIN-Term Transatlantic Interdisciplinary consensus document. J Vasc Surg 2009;49:498-501.
9. Ramelet AA, Boisseau MR, Allegra C, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005;33:309-319.
10. Ramelet AA, Perrin M, Kern P, Bounameaux H. Phlebology. 5th ed. Issy les Moulineaux, France: Elsevier Masson; 2008.
11. Bergan JJ, Schmid-Schönbein G, Coleridge-Smith P, Nicolaides A, Boisseau M, Eklof B. Chronic venous disease. N Engl J Med 2006;355:488-498.
12. Ono T, Bergan JJ, Schmid-Schönbein GN, Takase S. Monocyte infiltration into venous valves. J Vasc Surg 1998;27:158-166.
13. Takase S, Bergan JJ, Schmid-Schönbein GW. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg 2000;14:427-435.
14. Takase S, Lerond L, Bergan JJ, Schmid-Schönbein GW. Enhancement of reperfusion injury by elevation of microvascular pressures. Am J Physiol Heart Circ 2002;282:H1387-H1394.
15. Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schönbein GW. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg 2004;28:484-493.
16. Pascarella L, Lulic D, Penn AH, et al. Mechanisms in Experimental Venous Valve Failure and their Modification by Daflon 500 mg. Eur J Vasc Endovasc Surg 2008;35:102-110.
17. Danziger N. Hypothesis on the origin of pain. Phlebolymphology 2008;15:107-114.
18. Amiel M, Barbe R. Etude du délai et de la durée d'action de Daflon 500mg. JIM 1987;88:22-24.
19. Barbe R, Amiel M. Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology 1992;7 (suppl 2):41-44.
20. Amiel M, Barbe R. Etude de l'activité pharmacodynamique de Daflon 500mg. Ann Cardiol Angéiol 1998;47:185-188.
21. Ibegbuna V, Nicolaides AN, Sowade O, Leon M, Geroulakos G. Venous elasticity after treatment with Daflon 500 mg. Angiology 1997;48:45-49.
22. Behar A, Lagrue G, Cohen-Boulakia F, et al. Study of capillary filtration by double labelling I131-albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg. Int Angiol 1988;7(2 suppl):35-38.
23. Cesarone MR, Laurora G, De Sanctis MT, et al. Capillary filtration and ankle edema in patients with venous hypertension: effects of Daflon. Angiology 1993;44:57-61.
24. Struckmann JR. Clinical efficacy of micronized purified flavonoid fraction: an overview. J Vasc Res 1999;36(Suppl 1):37-41.
25. Allegra C, Bartolo MJr, Carioti B, et al. Microlymphography: assessment of Daflon 500 mg activity in patients with chronic venous insufficiency. Lymphology 1997;31(Suppl):12-16.
26. Nicolaides AN, Allegra C, Bergan J, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol 2008;27:1-59.
27. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005;30:198-208.
28. Kearon C, et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:454S-545S.
29. Coleridge Smith PD. Drug treatment of varicose veins, venous edema, and ulcers. In: Gloviczki P, ed. Handbook of Venous Disorders: Guidelines of the American Venous Forum. 3rd ed. London, UK: Hodder Arnold; 2009: 359-365.
30. Chassignolle J-F, Amiel M, Lanfranchi G, et al. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle. J Int Med 1987;99(Suppl):32-37.
31. Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology 1994;9:67-70.
32. Cospite M, Dominici A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol 1989;8(4 Suppl):61-65.
33. Pokrovsky AV, Saveljev VS, Kirienko AI et al. Surgical correction of varicose vein disease under micronized diosmin protection (results of the Russian multicenter controlled trial DEFANS). Angiol Sosud Khir. 2007;13(2):47-55.
34. Pokrovsky AV, Saveljev VS, Kirienko AI et al. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). Phlebolymphology. 2008;15:45-51.
35. Veverkova L, Kalac J, Jedlicka V et al. Analysis of surgical procedures on the vena saphena magna in the Czech Republic and an effect of Detralex during its stripping. Rozhl Chir. 2005;84:410-12.
36. Veverkova L, Kalac J, Jedlicka V et al. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg to postoperative symptoms. Phlebolymphology 2006;13:195-201.
37. Simsek M, Burak F, Taskin O. Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial. Clin Exp Obstet Gynecol. 2007;34:96-98.
38. Laurent R, Gilly R, Frileux C. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. Int Angiol. 1988;7(Suppl):S34-S43.
39. Blume J, Langenbahn H, de Champvallins M. Quantification of oedema using the volometer technique: therapeutic application of DAFLON 500 mg in chronic venous insufficiency. Phlebology 1992; (Suppl 2):37-40.
40. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Angiology 2002;53:245-256.
41. Glinski W, Chodynicka B, Roszkiewicz J, et al. The beneficial augmentative effects of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open multicenter, controlled, randomized study. Phlebology 1999;14:151-157.
42. Roztocil K, Stvrtinova V, Strejcek J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol 2003;122:24-31.
43. Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997;48:77-85.